Ionis axes eye disease from targets of Roche-partnered prospect after data disappoint

Another of Ionis Pharmaceuticals’ key midphase readouts has fallen short of expectations, prompting the biotech to stop studying the Roche-partnered candidate in an advanced form of age-related macular degeneration.